TCP11L2

Across TCGA pan-cancer cohorts, TCP11L2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TCP11L2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher TCP11L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TCP11L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, UCEC, and LUSC are the cancer types where TCP11L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.172	0.870	<.001	18	view →
UCEC	DFS	Median	All	0.831	0.630	.014	14	view →
LUSC	DFS	Median	All	0.205	0.648	.003	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
BRCA	OS	Median	All	0.757	0.963	.028	6	view →
HNSC	OS	Median	All	0.125	0.362	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TCP11L2–COAD (OS)

Open the COAD breakdown →